Cardiometabolic Health and Inflammatory Resolution
ConditionVolunteers
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorGöteborg University
About this trial
The aim of this study is to determine how inflammatory resolution impacts cardiometabolic health and disease in subjects that are either lean (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2) or obese (\>30.0 kg/m2).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Informed signed consent has been obtained from the volunteer.
The volunteer has a BMI greater than 18.5 kg/m2
Disqualifiers
The study staff contacting a potential participant perceives that the individual has difficulty understanding the information.
An MD determines that the individual is on too many medications to participate
The individual takes a medication that is approved by the MD, but he/she is not willing or not able to wait with any potential morning medication until after their fasted blood-draw.
The individual is younger than 18 years (relevant for the FAINT-1 and FAINT-2 cohorts)
Trial population
Subjects are recruited either via open adds of after having indicated in previous study registers that they are interested in participating as volunteers in future studies.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
200 Participants
are grouped into 6 trial groups6
Trial groupsSee each trial group below.
Group A: Lean and metabolically healthy
Group B: Lean and metabolically unhealthy
Group C: Overweight and metabolically healthy
Group D: Overweight and metabolically unhealthy
Group E: Obese and metabolically healthy
Group F: Obese and metabolically unhealthy
Trial outcomes
Primary outcomes
1
Inflammatory status
The inflammatory status, defined as CRP levels and ability to respond to pro-resolving therapeutics, will be studied in all 6 groups
Time frame
2027Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov